uPAR-Targeting Cytotoxic Antibody–Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications
Cells · 2026
DOI: 10.3390/cells15090803 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Handan Xiang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Immunology, Merck & Co., Inc., Rahway, NJ 07065, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Myeloid Cells, Inflammation, Arthritis, Rheumatoid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by synovial inflammation and progressive joint destruction. There is no cure, and patient responses to current therapies vary, reflecting underlying pathogenic heterogeneity. Leveraging single-cell RNA sequencing (scRNA-seq) of RA synovium, we identified a PLAUR/uPAR-high myeloid subset that co-expresses pathogenic mediators, including IL1B and CXCL8. To target these cells, we developed anti-uPAR antibody–drug conjugates (ADCs) and evaluated various payloads in vitro and in vivo. ADCs bearing BCL-2 family inhibitors selectively induced apoptosis in proinflammatory human monocytes and macrophages with elevated uPAR, while sparing unstimulated monocytes with low basal uPAR in vitro. The treatment also reduced CXCL8 secretion. Given that murine myeloid cells exhibited lower uPAR expression and reduced sensitivity to BCL-2 family inhibitors, we used a monomethyl auristatin F (MMAF) payload to demonstrate in vivo proof-of-concept. In an air-pouch model, the anti-uPAR–MMAF conjugate reduced uPARhighCD11b+F4/80+ macrophages by 39% compared with the isotype control. Together, our study underscores the potential of ADCs to eliminate disease-relevant cell types with inducible cell surface markers. This work opens new avenues for exploring cytotoxic ADCs as targeted therapies for autoimmune and inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Immunology, Merck & Co., Inc., Rahway, NJ 07065, USA.
- Discovery Biologics, Merck & Co., Inc., Rahway, NJ 07065, USA.
- Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA.
- Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ 07065, USA.
- Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., Rahway, NJ 07065, USA.
- Data, AI and Genome Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA.
ORCID-Profile: Handan Xiang, Arjun Baghela, Marc A Sze, Gretchen A Baltus, Elisabeth H Vollmann
Zitieren
APA
Xiang, H., Mortenson, G. P., Lang, S. B., Jakkaraju, S., Chirala, A., Zhu, Y., Jia, M., Wen, J., Chen, Y., Baghela, A., Chen, Y. C., Sze, M. A., Hegde, L. G., Zhang-Hoover, J., Willingham, A., Handa, M., Chi, A., Baltus, G. A., Kamath, R. V., …, & Vollmann, E. H. (2026). uPAR-Targeting Cytotoxic Antibody–Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications. Cells. https://doi.org/10.3390/cells15090803
Vancouver
Xiang H, Mortenson GP, Lang SB, Jakkaraju S, Chirala A, Zhu Y, et al. uPAR-Targeting Cytotoxic Antibody–Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications. Cells. 2026. doi:10.3390/cells15090803
BibTeX
@article{Xiang2026,
author = {Xiang, Handan and Mortenson, Grace Pham and Lang, Simon B and Jakkaraju, Sriram and Chirala, Anirudh and Zhu, Yimin and Jia, Mengxuan and Wen, Jianzhong and Chen, Ying and Baghela, Arjun and Chen, Yen-Cheng and Sze, Marc A and Hegde, Laxminarayan G and Zhang-Hoover, Jie and Willingham, Aarron and Handa, Masahisa and Chi, An and Baltus, Gretchen A and Kamath, Rajesh V and Levesque, Marc C and Vollmann, Elisabeth H},
title = {uPAR-Targeting Cytotoxic Antibody–Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15090803}
}
EUVIMED